Today it was reported that a Director at Meridian Bioscience Inc (NASDAQ: VIVO), Dwight Ellingwood, exercised options to buy 1,000 VIVO shares at $12.80 a share, for a total transaction value of $12.8K.
Following this transaction Dwight Ellingwood’s holding in the company was increased by 14.29% to a total of $119K.
Based on Meridian Bioscience Inc’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $51.74 million and quarterly net profit of $6.83 million. In comparison, last year the company earned revenue of $49.7 million and had a net profit of $5.73 million. VIVO’s market cap is $629.9M and the company has a P/E ratio of 26.55. Currently, Meridian Bioscience Inc has an average volume of 31.1K.
The insider sentiment on Meridian Bioscience Inc has been positive according to 30 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Meridian Bioscience, Inc. engages in the development, manufacture, sale, and distribution of diagnostic test kits, purified reagents, and related products. It also offers biopharmaceutical enabling technologies. It operates through the Diagnostics and Life Science segments.